nodes	percent_of_prediction	percent_of_DWPC	metapath
Regorafenib—NTRK1—peripheral nervous system neoplasm	0.419	0.877	CbGaD
Regorafenib—ABCB1—peripheral nervous system neoplasm	0.0587	0.123	CbGaD
Regorafenib—ABCG2—Topotecan—peripheral nervous system neoplasm	0.0339	0.12	CbGbCtD
Regorafenib—UGT1A1—Etoposide—peripheral nervous system neoplasm	0.0241	0.085	CbGbCtD
Regorafenib—ABCG2—Dactinomycin—peripheral nervous system neoplasm	0.0235	0.0829	CbGbCtD
Regorafenib—CYP2B6—Tretinoin—peripheral nervous system neoplasm	0.0222	0.0782	CbGbCtD
Regorafenib—CYP2C8—Tretinoin—peripheral nervous system neoplasm	0.0168	0.0592	CbGbCtD
Regorafenib—ABCG2—Vincristine—peripheral nervous system neoplasm	0.0145	0.051	CbGbCtD
Regorafenib—ABCG2—Cisplatin—peripheral nervous system neoplasm	0.0135	0.0476	CbGbCtD
Regorafenib—ABCG2—Etoposide—peripheral nervous system neoplasm	0.0133	0.0468	CbGbCtD
Regorafenib—ABCB1—Alitretinoin—peripheral nervous system neoplasm	0.0122	0.0431	CbGbCtD
Regorafenib—ABCB1—Topotecan—peripheral nervous system neoplasm	0.0122	0.0431	CbGbCtD
Regorafenib—CYP2C9—Tretinoin—peripheral nervous system neoplasm	0.0117	0.0413	CbGbCtD
Regorafenib—CYP2B6—Cisplatin—peripheral nervous system neoplasm	0.00949	0.0335	CbGbCtD
Regorafenib—ABCG2—Doxorubicin—peripheral nervous system neoplasm	0.00904	0.0319	CbGbCtD
Regorafenib—ABCB1—Dactinomycin—peripheral nervous system neoplasm	0.00847	0.0299	CbGbCtD
Regorafenib—CYP3A4—Topotecan—peripheral nervous system neoplasm	0.00732	0.0258	CbGbCtD
Regorafenib—CYP2C8—Etoposide—peripheral nervous system neoplasm	0.00706	0.0249	CbGbCtD
Regorafenib—CYP3A4—Tretinoin—peripheral nervous system neoplasm	0.00681	0.024	CbGbCtD
Regorafenib—CYP2B6—Doxorubicin—peripheral nervous system neoplasm	0.00636	0.0224	CbGbCtD
Regorafenib—ABCB1—Vincristine—peripheral nervous system neoplasm	0.00522	0.0184	CbGbCtD
Regorafenib—CYP2C9—Cisplatin—peripheral nervous system neoplasm	0.00501	0.0177	CbGbCtD
Regorafenib—ABCB1—Cisplatin—peripheral nervous system neoplasm	0.00487	0.0172	CbGbCtD
Regorafenib—ABCB1—Etoposide—peripheral nervous system neoplasm	0.00478	0.0169	CbGbCtD
Regorafenib—ABCB1—Doxorubicin—peripheral nervous system neoplasm	0.00326	0.0115	CbGbCtD
Regorafenib—CYP3A4—Vincristine—peripheral nervous system neoplasm	0.00313	0.011	CbGbCtD
Regorafenib—CYP3A4—Etoposide—peripheral nervous system neoplasm	0.00286	0.0101	CbGbCtD
Regorafenib—FGFR2—skull—peripheral nervous system neoplasm	0.00222	0.119	CbGeAlD
Regorafenib—CYP3A4—Doxorubicin—peripheral nervous system neoplasm	0.00195	0.00689	CbGbCtD
Regorafenib—NTRK1—trigeminal ganglion—peripheral nervous system neoplasm	0.00149	0.0799	CbGeAlD
Regorafenib—EPHX2—parotid gland—peripheral nervous system neoplasm	0.000707	0.0379	CbGeAlD
Regorafenib—FGFR1—trigeminal ganglion—peripheral nervous system neoplasm	0.000666	0.0357	CbGeAlD
Regorafenib—RET—trigeminal ganglion—peripheral nervous system neoplasm	0.000596	0.032	CbGeAlD
Regorafenib—EPHA2—trigeminal ganglion—peripheral nervous system neoplasm	0.000557	0.0298	CbGeAlD
Regorafenib—TEK—trigeminal ganglion—peripheral nervous system neoplasm	0.000543	0.0291	CbGeAlD
Regorafenib—FLT1—trigeminal ganglion—peripheral nervous system neoplasm	0.000525	0.0281	CbGeAlD
Regorafenib—EPHA2—parotid gland—peripheral nervous system neoplasm	0.000525	0.0281	CbGeAlD
Regorafenib—RAF1—trigeminal ganglion—peripheral nervous system neoplasm	0.000522	0.028	CbGeAlD
Regorafenib—FGFR2—brainstem—peripheral nervous system neoplasm	0.000501	0.0269	CbGeAlD
Regorafenib—FLT1—parotid gland—peripheral nervous system neoplasm	0.000495	0.0265	CbGeAlD
Regorafenib—RAF1—parotid gland—peripheral nervous system neoplasm	0.000493	0.0264	CbGeAlD
Regorafenib—DDR2—cerebellum—peripheral nervous system neoplasm	0.000484	0.0259	CbGeAlD
Regorafenib—RAF1—brainstem—peripheral nervous system neoplasm	0.000462	0.0248	CbGeAlD
Regorafenib—MAPK11—cerebellum—peripheral nervous system neoplasm	0.000459	0.0246	CbGeAlD
Regorafenib—KDR—trigeminal ganglion—peripheral nervous system neoplasm	0.000444	0.0238	CbGeAlD
Regorafenib—KDR—parotid gland—peripheral nervous system neoplasm	0.000419	0.0224	CbGeAlD
Regorafenib—KIT—trigeminal ganglion—peripheral nervous system neoplasm	0.000394	0.0211	CbGeAlD
Regorafenib—PDGFRB—trigeminal ganglion—peripheral nervous system neoplasm	0.000384	0.0206	CbGeAlD
Regorafenib—KIT—parotid gland—peripheral nervous system neoplasm	0.000371	0.0199	CbGeAlD
Regorafenib—PDGFRB—parotid gland—peripheral nervous system neoplasm	0.000362	0.0194	CbGeAlD
Regorafenib—ABL1—Doxorubicin—Epirubicin—peripheral nervous system neoplasm	0.000361	0.173	CbGdCrCtD
Regorafenib—ABL1—Idarubicin—Epirubicin—peripheral nervous system neoplasm	0.000361	0.173	CbGdCrCtD
Regorafenib—ABL1—Daunorubicin—Epirubicin—peripheral nervous system neoplasm	0.000361	0.173	CbGdCrCtD
Regorafenib—KIT—brainstem—peripheral nervous system neoplasm	0.000348	0.0187	CbGeAlD
Regorafenib—ABL1—trigeminal ganglion—peripheral nervous system neoplasm	0.000343	0.0184	CbGeAlD
Regorafenib—BRAF—cerebellum—peripheral nervous system neoplasm	0.000342	0.0183	CbGeAlD
Regorafenib—ABL1—Epirubicin—Doxorubicin—peripheral nervous system neoplasm	0.000334	0.16	CbGdCrCtD
Regorafenib—ABL1—Idarubicin—Doxorubicin—peripheral nervous system neoplasm	0.000334	0.16	CbGdCrCtD
Regorafenib—ABL1—Daunorubicin—Doxorubicin—peripheral nervous system neoplasm	0.000334	0.16	CbGdCrCtD
Regorafenib—EPHX2—cerebellum—peripheral nervous system neoplasm	0.000327	0.0175	CbGeAlD
Regorafenib—ABL1—parotid gland—peripheral nervous system neoplasm	0.000323	0.0173	CbGeAlD
Regorafenib—ABL1—brainstem—peripheral nervous system neoplasm	0.000303	0.0162	CbGeAlD
Regorafenib—FGFR1—cerebellum—peripheral nervous system neoplasm	0.000291	0.0156	CbGeAlD
Regorafenib—RET—cerebellum—peripheral nervous system neoplasm	0.00026	0.0139	CbGeAlD
Regorafenib—FGFR2—cerebellum—peripheral nervous system neoplasm	0.000247	0.0132	CbGeAlD
Regorafenib—TEK—cerebellum—peripheral nervous system neoplasm	0.000237	0.0127	CbGeAlD
Regorafenib—FLT1—cerebellum—peripheral nervous system neoplasm	0.000229	0.0123	CbGeAlD
Regorafenib—RAF1—cerebellum—peripheral nervous system neoplasm	0.000228	0.0122	CbGeAlD
Regorafenib—Sorafenib—ABCB1—peripheral nervous system neoplasm	0.000227	1	CrCbGaD
Regorafenib—ABCG2—trigeminal ganglion—peripheral nervous system neoplasm	0.000216	0.0116	CbGeAlD
Regorafenib—PDGFRA—cerebellum—peripheral nervous system neoplasm	0.000215	0.0115	CbGeAlD
Regorafenib—ABCG2—parotid gland—peripheral nervous system neoplasm	0.000204	0.0109	CbGeAlD
Regorafenib—KDR—cerebellum—peripheral nervous system neoplasm	0.000194	0.0104	CbGeAlD
Regorafenib—KIT—cerebellum—peripheral nervous system neoplasm	0.000172	0.0092	CbGeAlD
Regorafenib—Decreased appetite—Isotretinoin—peripheral nervous system neoplasm	0.00017	0.00169	CcSEcCtD
Regorafenib—Fatigue—Topotecan—peripheral nervous system neoplasm	0.00017	0.00169	CcSEcCtD
Regorafenib—Gastrointestinal disorder—Isotretinoin—peripheral nervous system neoplasm	0.000169	0.00168	CcSEcCtD
Regorafenib—Gastrointestinal disorder—Tretinoin—peripheral nervous system neoplasm	0.000169	0.00168	CcSEcCtD
Regorafenib—Fatigue—Tretinoin—peripheral nervous system neoplasm	0.000169	0.00167	CcSEcCtD
Regorafenib—Fatigue—Isotretinoin—peripheral nervous system neoplasm	0.000169	0.00167	CcSEcCtD
Regorafenib—Pain—Topotecan—peripheral nervous system neoplasm	0.000169	0.00167	CcSEcCtD
Regorafenib—Anaemia—Alitretinoin—peripheral nervous system neoplasm	0.000168	0.00167	CcSEcCtD
Regorafenib—Decreased appetite—Melphalan—peripheral nervous system neoplasm	0.000168	0.00167	CcSEcCtD
Regorafenib—PDGFRB—cerebellum—peripheral nervous system neoplasm	0.000168	0.00898	CbGeAlD
Regorafenib—Pain—Tretinoin—peripheral nervous system neoplasm	0.000167	0.00166	CcSEcCtD
Regorafenib—Pain—Isotretinoin—peripheral nervous system neoplasm	0.000167	0.00166	CcSEcCtD
Regorafenib—Gastrointestinal disorder—Melphalan—peripheral nervous system neoplasm	0.000167	0.00166	CcSEcCtD
Regorafenib—Fatigue—Melphalan—peripheral nervous system neoplasm	0.000166	0.00165	CcSEcCtD
Regorafenib—Pain—Melphalan—peripheral nervous system neoplasm	0.000165	0.00164	CcSEcCtD
Regorafenib—Cardiac disorder—Cisplatin—peripheral nervous system neoplasm	0.000165	0.00164	CcSEcCtD
Regorafenib—Neoplasm—Epirubicin—peripheral nervous system neoplasm	0.000164	0.00163	CcSEcCtD
Regorafenib—Anaemia—Vincristine—peripheral nervous system neoplasm	0.000162	0.00161	CcSEcCtD
Regorafenib—Gastrointestinal pain—Topotecan—peripheral nervous system neoplasm	0.000161	0.0016	CcSEcCtD
Regorafenib—Urinary tract disorder—Etoposide—peripheral nervous system neoplasm	0.000161	0.0016	CcSEcCtD
Regorafenib—Mediastinal disorder—Cisplatin—peripheral nervous system neoplasm	0.00016	0.00159	CcSEcCtD
Regorafenib—Gastrointestinal pain—Isotretinoin—peripheral nervous system neoplasm	0.00016	0.00159	CcSEcCtD
Regorafenib—Gastrointestinal pain—Tretinoin—peripheral nervous system neoplasm	0.00016	0.00159	CcSEcCtD
Regorafenib—Urethral disorder—Etoposide—peripheral nervous system neoplasm	0.00016	0.00159	CcSEcCtD
Regorafenib—Infection—Dactinomycin—peripheral nervous system neoplasm	0.000159	0.00158	CcSEcCtD
Regorafenib—Alopecia—Cisplatin—peripheral nervous system neoplasm	0.000157	0.00156	CcSEcCtD
Regorafenib—Hypertension—Alitretinoin—peripheral nervous system neoplasm	0.000157	0.00156	CcSEcCtD
Regorafenib—Leukopenia—Vincristine—peripheral nervous system neoplasm	0.000157	0.00156	CcSEcCtD
Regorafenib—Thrombocytopenia—Dactinomycin—peripheral nervous system neoplasm	0.000156	0.00155	CcSEcCtD
Regorafenib—Body temperature increased—Topotecan—peripheral nervous system neoplasm	0.000156	0.00155	CcSEcCtD
Regorafenib—Abdominal pain—Topotecan—peripheral nervous system neoplasm	0.000156	0.00155	CcSEcCtD
Regorafenib—Malnutrition—Cisplatin—peripheral nervous system neoplasm	0.000155	0.00154	CcSEcCtD
Regorafenib—Body temperature increased—Tretinoin—peripheral nervous system neoplasm	0.000155	0.00154	CcSEcCtD
Regorafenib—Abdominal pain—Isotretinoin—peripheral nervous system neoplasm	0.000155	0.00154	CcSEcCtD
Regorafenib—Body temperature increased—Isotretinoin—peripheral nervous system neoplasm	0.000155	0.00154	CcSEcCtD
Regorafenib—Abdominal pain—Tretinoin—peripheral nervous system neoplasm	0.000155	0.00154	CcSEcCtD
Regorafenib—Erythema multiforme—Etoposide—peripheral nervous system neoplasm	0.000154	0.00153	CcSEcCtD
Regorafenib—Unspecified disorder of skin and subcutaneous tissue—Alitretinoin—peripheral nervous system neoplasm	0.000153	0.00152	CcSEcCtD
Regorafenib—Neoplasm—Doxorubicin—peripheral nervous system neoplasm	0.000152	0.00151	CcSEcCtD
Regorafenib—Dry mouth—Alitretinoin—peripheral nervous system neoplasm	0.000151	0.0015	CcSEcCtD
Regorafenib—Cardiac disorder—Etoposide—peripheral nervous system neoplasm	0.000151	0.0015	CcSEcCtD
Regorafenib—Hypertension—Vincristine—peripheral nervous system neoplasm	0.000151	0.0015	CcSEcCtD
Regorafenib—ABL1—cerebellum—peripheral nervous system neoplasm	0.000149	0.00801	CbGeAlD
Regorafenib—Angiopathy—Etoposide—peripheral nervous system neoplasm	0.000148	0.00147	CcSEcCtD
Regorafenib—Infection—Alitretinoin—peripheral nervous system neoplasm	0.000147	0.00146	CcSEcCtD
Regorafenib—Mediastinal disorder—Etoposide—peripheral nervous system neoplasm	0.000147	0.00146	CcSEcCtD
Regorafenib—Nervous system disorder—Alitretinoin—peripheral nervous system neoplasm	0.000145	0.00144	CcSEcCtD
Regorafenib—Thrombocytopenia—Alitretinoin—peripheral nervous system neoplasm	0.000145	0.00144	CcSEcCtD
Regorafenib—Tremor—Cisplatin—peripheral nervous system neoplasm	0.000145	0.00144	CcSEcCtD
Regorafenib—Skin disorder—Alitretinoin—peripheral nervous system neoplasm	0.000144	0.00143	CcSEcCtD
Regorafenib—Alopecia—Etoposide—peripheral nervous system neoplasm	0.000144	0.00143	CcSEcCtD
Regorafenib—Anaemia—Cisplatin—peripheral nervous system neoplasm	0.000143	0.00142	CcSEcCtD
Regorafenib—Infection—Vincristine—peripheral nervous system neoplasm	0.000142	0.00141	CcSEcCtD
Regorafenib—Asthenia—Topotecan—peripheral nervous system neoplasm	0.000141	0.0014	CcSEcCtD
Regorafenib—Asthenia—Isotretinoin—peripheral nervous system neoplasm	0.00014	0.00139	CcSEcCtD
Regorafenib—Asthenia—Tretinoin—peripheral nervous system neoplasm	0.00014	0.00139	CcSEcCtD
Regorafenib—Nervous system disorder—Vincristine—peripheral nervous system neoplasm	0.00014	0.00139	CcSEcCtD
Regorafenib—Thrombocytopenia—Vincristine—peripheral nervous system neoplasm	0.00014	0.00139	CcSEcCtD
Regorafenib—Decreased appetite—Dactinomycin—peripheral nervous system neoplasm	0.000139	0.00138	CcSEcCtD
Regorafenib—Leukopenia—Cisplatin—peripheral nervous system neoplasm	0.000138	0.00138	CcSEcCtD
Regorafenib—Asthenia—Melphalan—peripheral nervous system neoplasm	0.000138	0.00138	CcSEcCtD
Regorafenib—Fatigue—Dactinomycin—peripheral nervous system neoplasm	0.000138	0.00137	CcSEcCtD
Regorafenib—Pain—Dactinomycin—peripheral nervous system neoplasm	0.000137	0.00136	CcSEcCtD
Regorafenib—Diarrhoea—Topotecan—peripheral nervous system neoplasm	0.000135	0.00134	CcSEcCtD
Regorafenib—Diarrhoea—Tretinoin—peripheral nervous system neoplasm	0.000134	0.00133	CcSEcCtD
Regorafenib—Diarrhoea—Isotretinoin—peripheral nervous system neoplasm	0.000134	0.00133	CcSEcCtD
Regorafenib—Hyponatraemia—Epirubicin—peripheral nervous system neoplasm	0.000132	0.00132	CcSEcCtD
Regorafenib—Diarrhoea—Melphalan—peripheral nervous system neoplasm	0.000132	0.00131	CcSEcCtD
Regorafenib—Anaemia—Etoposide—peripheral nervous system neoplasm	0.000131	0.0013	CcSEcCtD
Regorafenib—Unspecified disorder of skin and subcutaneous tissue—Cisplatin—peripheral nervous system neoplasm	0.000131	0.0013	CcSEcCtD
Regorafenib—Gastrointestinal pain—Dactinomycin—peripheral nervous system neoplasm	0.000131	0.0013	CcSEcCtD
Regorafenib—Decreased appetite—Alitretinoin—peripheral nervous system neoplasm	0.000129	0.00128	CcSEcCtD
Regorafenib—Gastrointestinal disorder—Alitretinoin—peripheral nervous system neoplasm	0.000128	0.00127	CcSEcCtD
Regorafenib—Fatigue—Alitretinoin—peripheral nervous system neoplasm	0.000128	0.00127	CcSEcCtD
Regorafenib—Leukopenia—Etoposide—peripheral nervous system neoplasm	0.000127	0.00126	CcSEcCtD
Regorafenib—Pain—Alitretinoin—peripheral nervous system neoplasm	0.000127	0.00126	CcSEcCtD
Regorafenib—Body temperature increased—Dactinomycin—peripheral nervous system neoplasm	0.000126	0.00125	CcSEcCtD
Regorafenib—Abdominal pain—Dactinomycin—peripheral nervous system neoplasm	0.000126	0.00125	CcSEcCtD
Regorafenib—Infection—Cisplatin—peripheral nervous system neoplasm	0.000125	0.00125	CcSEcCtD
Regorafenib—Vomiting—Topotecan—peripheral nervous system neoplasm	0.000125	0.00124	CcSEcCtD
Regorafenib—Vomiting—Isotretinoin—peripheral nervous system neoplasm	0.000124	0.00123	CcSEcCtD
Regorafenib—Vomiting—Tretinoin—peripheral nervous system neoplasm	0.000124	0.00123	CcSEcCtD
Regorafenib—Rash—Topotecan—peripheral nervous system neoplasm	0.000124	0.00123	CcSEcCtD
Regorafenib—Dermatitis—Topotecan—peripheral nervous system neoplasm	0.000124	0.00123	CcSEcCtD
Regorafenib—Decreased appetite—Vincristine—peripheral nervous system neoplasm	0.000124	0.00123	CcSEcCtD
Regorafenib—Nervous system disorder—Cisplatin—peripheral nervous system neoplasm	0.000124	0.00123	CcSEcCtD
Regorafenib—Thrombocytopenia—Cisplatin—peripheral nervous system neoplasm	0.000124	0.00123	CcSEcCtD
Regorafenib—Headache—Topotecan—peripheral nervous system neoplasm	0.000123	0.00123	CcSEcCtD
Regorafenib—Rash—Isotretinoin—peripheral nervous system neoplasm	0.000123	0.00122	CcSEcCtD
Regorafenib—Rash—Tretinoin—peripheral nervous system neoplasm	0.000123	0.00122	CcSEcCtD
Regorafenib—Gastrointestinal disorder—Vincristine—peripheral nervous system neoplasm	0.000123	0.00122	CcSEcCtD
Regorafenib—Dermatitis—Tretinoin—peripheral nervous system neoplasm	0.000123	0.00122	CcSEcCtD
Regorafenib—Dermatitis—Isotretinoin—peripheral nervous system neoplasm	0.000123	0.00122	CcSEcCtD
Regorafenib—Fatigue—Vincristine—peripheral nervous system neoplasm	0.000123	0.00122	CcSEcCtD
Regorafenib—Vomiting—Melphalan—peripheral nervous system neoplasm	0.000123	0.00122	CcSEcCtD
Regorafenib—Skin disorder—Cisplatin—peripheral nervous system neoplasm	0.000123	0.00122	CcSEcCtD
Regorafenib—Hyponatraemia—Doxorubicin—peripheral nervous system neoplasm	0.000123	0.00122	CcSEcCtD
Regorafenib—Headache—Isotretinoin—peripheral nervous system neoplasm	0.000122	0.00122	CcSEcCtD
Regorafenib—Headache—Tretinoin—peripheral nervous system neoplasm	0.000122	0.00122	CcSEcCtD
Regorafenib—Hypertension—Etoposide—peripheral nervous system neoplasm	0.000122	0.00122	CcSEcCtD
Regorafenib—Pain—Vincristine—peripheral nervous system neoplasm	0.000122	0.00121	CcSEcCtD
Regorafenib—Rash—Melphalan—peripheral nervous system neoplasm	0.000122	0.00121	CcSEcCtD
Regorafenib—Dermatitis—Melphalan—peripheral nervous system neoplasm	0.000122	0.00121	CcSEcCtD
Regorafenib—Gastrointestinal pain—Alitretinoin—peripheral nervous system neoplasm	0.000121	0.0012	CcSEcCtD
Regorafenib—Dry skin—Epirubicin—peripheral nervous system neoplasm	0.000121	0.0012	CcSEcCtD
Regorafenib—Hypokalaemia—Epirubicin—peripheral nervous system neoplasm	0.00012	0.00119	CcSEcCtD
Regorafenib—Unspecified disorder of skin and subcutaneous tissue—Etoposide—peripheral nervous system neoplasm	0.00012	0.00119	CcSEcCtD
Regorafenib—Toxic epidermal necrolysis—Epirubicin—peripheral nervous system neoplasm	0.000119	0.00118	CcSEcCtD
Regorafenib—Aspartate aminotransferase increased—Epirubicin—peripheral nervous system neoplasm	0.000119	0.00118	CcSEcCtD
Regorafenib—Body temperature increased—Alitretinoin—peripheral nervous system neoplasm	0.000117	0.00116	CcSEcCtD
Regorafenib—Abdominal pain—Alitretinoin—peripheral nervous system neoplasm	0.000117	0.00116	CcSEcCtD
Regorafenib—Nausea—Topotecan—peripheral nervous system neoplasm	0.000117	0.00116	CcSEcCtD
Regorafenib—Gastrointestinal pain—Vincristine—peripheral nervous system neoplasm	0.000117	0.00116	CcSEcCtD
Regorafenib—Alanine aminotransferase increased—Epirubicin—peripheral nervous system neoplasm	0.000116	0.00116	CcSEcCtD
Regorafenib—Nausea—Tretinoin—peripheral nervous system neoplasm	0.000116	0.00115	CcSEcCtD
Regorafenib—Nausea—Isotretinoin—peripheral nervous system neoplasm	0.000116	0.00115	CcSEcCtD
Regorafenib—Infection—Etoposide—peripheral nervous system neoplasm	0.000115	0.00114	CcSEcCtD
Regorafenib—Asthenia—Dactinomycin—peripheral nervous system neoplasm	0.000115	0.00114	CcSEcCtD
Regorafenib—Nausea—Melphalan—peripheral nervous system neoplasm	0.000115	0.00114	CcSEcCtD
Regorafenib—Thrombocytopenia—Etoposide—peripheral nervous system neoplasm	0.000113	0.00112	CcSEcCtD
Regorafenib—Body temperature increased—Vincristine—peripheral nervous system neoplasm	0.000113	0.00112	CcSEcCtD
Regorafenib—Abdominal pain—Vincristine—peripheral nervous system neoplasm	0.000113	0.00112	CcSEcCtD
Regorafenib—Skin disorder—Etoposide—peripheral nervous system neoplasm	0.000112	0.00112	CcSEcCtD
Regorafenib—Dry skin—Doxorubicin—peripheral nervous system neoplasm	0.000112	0.00111	CcSEcCtD
Regorafenib—Hypokalaemia—Doxorubicin—peripheral nervous system neoplasm	0.000111	0.0011	CcSEcCtD
Regorafenib—Aspartate aminotransferase increased—Doxorubicin—peripheral nervous system neoplasm	0.00011	0.00109	CcSEcCtD
Regorafenib—Toxic epidermal necrolysis—Doxorubicin—peripheral nervous system neoplasm	0.00011	0.00109	CcSEcCtD
Regorafenib—Decreased appetite—Cisplatin—peripheral nervous system neoplasm	0.00011	0.00109	CcSEcCtD
Regorafenib—Diarrhoea—Dactinomycin—peripheral nervous system neoplasm	0.000109	0.00109	CcSEcCtD
Regorafenib—Gastrointestinal disorder—Cisplatin—peripheral nervous system neoplasm	0.000109	0.00108	CcSEcCtD
Regorafenib—Pain—Cisplatin—peripheral nervous system neoplasm	0.000108	0.00107	CcSEcCtD
Regorafenib—Alanine aminotransferase increased—Doxorubicin—peripheral nervous system neoplasm	0.000108	0.00107	CcSEcCtD
Regorafenib—Neutropenia—Epirubicin—peripheral nervous system neoplasm	0.000107	0.00106	CcSEcCtD
Regorafenib—ABCB1—trigeminal ganglion—peripheral nervous system neoplasm	0.000107	0.00571	CbGeAlD
Regorafenib—Asthenia—Alitretinoin—peripheral nervous system neoplasm	0.000106	0.00106	CcSEcCtD
Regorafenib—Weight decreased—Epirubicin—peripheral nervous system neoplasm	0.000103	0.00102	CcSEcCtD
Regorafenib—Asthenia—Vincristine—peripheral nervous system neoplasm	0.000102	0.00102	CcSEcCtD
Regorafenib—Infestation NOS—Epirubicin—peripheral nervous system neoplasm	0.000102	0.00101	CcSEcCtD
Regorafenib—Infestation—Epirubicin—peripheral nervous system neoplasm	0.000102	0.00101	CcSEcCtD
Regorafenib—Vomiting—Dactinomycin—peripheral nervous system neoplasm	0.000102	0.00101	CcSEcCtD
Regorafenib—Diarrhoea—Alitretinoin—peripheral nervous system neoplasm	0.000101	0.00101	CcSEcCtD
Regorafenib—Stevens-Johnson syndrome—Epirubicin—peripheral nervous system neoplasm	0.000101	0.001	CcSEcCtD
Regorafenib—Rash—Dactinomycin—peripheral nervous system neoplasm	0.000101	0.001	CcSEcCtD
Regorafenib—Decreased appetite—Etoposide—peripheral nervous system neoplasm	0.000101	0.000999	CcSEcCtD
Regorafenib—Gastrointestinal disorder—Etoposide—peripheral nervous system neoplasm	9.98e-05	0.000992	CcSEcCtD
Regorafenib—Body temperature increased—Cisplatin—peripheral nervous system neoplasm	9.98e-05	0.000991	CcSEcCtD
Regorafenib—Fatigue—Etoposide—peripheral nervous system neoplasm	9.97e-05	0.000991	CcSEcCtD
Regorafenib—Stomatitis—Epirubicin—peripheral nervous system neoplasm	9.91e-05	0.000984	CcSEcCtD
Regorafenib—Pain—Etoposide—peripheral nervous system neoplasm	9.89e-05	0.000983	CcSEcCtD
Regorafenib—Neutropenia—Doxorubicin—peripheral nervous system neoplasm	9.86e-05	0.00098	CcSEcCtD
Regorafenib—Diarrhoea—Vincristine—peripheral nervous system neoplasm	9.77e-05	0.00097	CcSEcCtD
Regorafenib—Hepatobiliary disease—Epirubicin—peripheral nervous system neoplasm	9.61e-05	0.000955	CcSEcCtD
Regorafenib—Weight decreased—Doxorubicin—peripheral nervous system neoplasm	9.54e-05	0.000948	CcSEcCtD
Regorafenib—Nausea—Dactinomycin—peripheral nervous system neoplasm	9.49e-05	0.000943	CcSEcCtD
Regorafenib—Gastrointestinal pain—Etoposide—peripheral nervous system neoplasm	9.46e-05	0.00094	CcSEcCtD
Regorafenib—ABCG2—cerebellum—peripheral nervous system neoplasm	9.42e-05	0.00505	CbGeAlD
Regorafenib—Vomiting—Alitretinoin—peripheral nervous system neoplasm	9.42e-05	0.000936	CcSEcCtD
Regorafenib—Infestation NOS—Doxorubicin—peripheral nervous system neoplasm	9.4e-05	0.000934	CcSEcCtD
Regorafenib—Infestation—Doxorubicin—peripheral nervous system neoplasm	9.4e-05	0.000934	CcSEcCtD
Regorafenib—Rash—Alitretinoin—peripheral nervous system neoplasm	9.34e-05	0.000928	CcSEcCtD
Regorafenib—Dermatitis—Alitretinoin—peripheral nervous system neoplasm	9.33e-05	0.000927	CcSEcCtD
Regorafenib—Stevens-Johnson syndrome—Doxorubicin—peripheral nervous system neoplasm	9.32e-05	0.000926	CcSEcCtD
Regorafenib—Headache—Alitretinoin—peripheral nervous system neoplasm	9.28e-05	0.000922	CcSEcCtD
Regorafenib—Haemoglobin—Epirubicin—peripheral nervous system neoplasm	9.17e-05	0.000911	CcSEcCtD
Regorafenib—Stomatitis—Doxorubicin—peripheral nervous system neoplasm	9.17e-05	0.000911	CcSEcCtD
Regorafenib—Body temperature increased—Etoposide—peripheral nervous system neoplasm	9.14e-05	0.000908	CcSEcCtD
Regorafenib—Abdominal pain—Etoposide—peripheral nervous system neoplasm	9.14e-05	0.000908	CcSEcCtD
Regorafenib—Haemorrhage—Epirubicin—peripheral nervous system neoplasm	9.12e-05	0.000907	CcSEcCtD
Regorafenib—Vomiting—Vincristine—peripheral nervous system neoplasm	9.08e-05	0.000902	CcSEcCtD
Regorafenib—Asthenia—Cisplatin—peripheral nervous system neoplasm	9.06e-05	0.0009	CcSEcCtD
Regorafenib—Urinary tract disorder—Epirubicin—peripheral nervous system neoplasm	9.01e-05	0.000895	CcSEcCtD
Regorafenib—Rash—Vincristine—peripheral nervous system neoplasm	9e-05	0.000894	CcSEcCtD
Regorafenib—Dermatitis—Vincristine—peripheral nervous system neoplasm	8.99e-05	0.000893	CcSEcCtD
Regorafenib—Connective tissue disorder—Epirubicin—peripheral nervous system neoplasm	8.97e-05	0.000891	CcSEcCtD
Regorafenib—Urethral disorder—Epirubicin—peripheral nervous system neoplasm	8.94e-05	0.000889	CcSEcCtD
Regorafenib—Headache—Vincristine—peripheral nervous system neoplasm	8.94e-05	0.000889	CcSEcCtD
Regorafenib—Hepatobiliary disease—Doxorubicin—peripheral nervous system neoplasm	8.89e-05	0.000884	CcSEcCtD
Regorafenib—Nausea—Alitretinoin—peripheral nervous system neoplasm	8.8e-05	0.000874	CcSEcCtD
Regorafenib—Diarrhoea—Cisplatin—peripheral nervous system neoplasm	8.64e-05	0.000858	CcSEcCtD
Regorafenib—Erythema multiforme—Epirubicin—peripheral nervous system neoplasm	8.63e-05	0.000857	CcSEcCtD
Regorafenib—Haemoglobin—Doxorubicin—peripheral nervous system neoplasm	8.49e-05	0.000843	CcSEcCtD
Regorafenib—Nausea—Vincristine—peripheral nervous system neoplasm	8.48e-05	0.000842	CcSEcCtD
Regorafenib—Cardiac disorder—Epirubicin—peripheral nervous system neoplasm	8.47e-05	0.000841	CcSEcCtD
Regorafenib—Haemorrhage—Doxorubicin—peripheral nervous system neoplasm	8.44e-05	0.000839	CcSEcCtD
Regorafenib—Urinary tract disorder—Doxorubicin—peripheral nervous system neoplasm	8.34e-05	0.000828	CcSEcCtD
Regorafenib—Asthenia—Etoposide—peripheral nervous system neoplasm	8.3e-05	0.000824	CcSEcCtD
Regorafenib—Connective tissue disorder—Doxorubicin—peripheral nervous system neoplasm	8.3e-05	0.000824	CcSEcCtD
Regorafenib—Angiopathy—Epirubicin—peripheral nervous system neoplasm	8.28e-05	0.000822	CcSEcCtD
Regorafenib—Urethral disorder—Doxorubicin—peripheral nervous system neoplasm	8.28e-05	0.000822	CcSEcCtD
Regorafenib—Mediastinal disorder—Epirubicin—peripheral nervous system neoplasm	8.22e-05	0.000817	CcSEcCtD
Regorafenib—Alopecia—Epirubicin—peripheral nervous system neoplasm	8.06e-05	0.000801	CcSEcCtD
Regorafenib—Vomiting—Cisplatin—peripheral nervous system neoplasm	8.03e-05	0.000797	CcSEcCtD
Regorafenib—Erythema multiforme—Doxorubicin—peripheral nervous system neoplasm	7.98e-05	0.000793	CcSEcCtD
Regorafenib—Rash—Cisplatin—peripheral nervous system neoplasm	7.96e-05	0.000791	CcSEcCtD
Regorafenib—Dermatitis—Cisplatin—peripheral nervous system neoplasm	7.95e-05	0.00079	CcSEcCtD
Regorafenib—Malnutrition—Epirubicin—peripheral nervous system neoplasm	7.94e-05	0.000789	CcSEcCtD
Regorafenib—Diarrhoea—Etoposide—peripheral nervous system neoplasm	7.91e-05	0.000786	CcSEcCtD
Regorafenib—Cardiac disorder—Doxorubicin—peripheral nervous system neoplasm	7.84e-05	0.000778	CcSEcCtD
Regorafenib—Angiopathy—Doxorubicin—peripheral nervous system neoplasm	7.66e-05	0.000761	CcSEcCtD
Regorafenib—Mediastinal disorder—Doxorubicin—peripheral nervous system neoplasm	7.61e-05	0.000756	CcSEcCtD
Regorafenib—Nausea—Cisplatin—peripheral nervous system neoplasm	7.5e-05	0.000745	CcSEcCtD
Regorafenib—Alopecia—Doxorubicin—peripheral nervous system neoplasm	7.46e-05	0.000741	CcSEcCtD
Regorafenib—Vomiting—Etoposide—peripheral nervous system neoplasm	7.35e-05	0.000731	CcSEcCtD
Regorafenib—Malnutrition—Doxorubicin—peripheral nervous system neoplasm	7.35e-05	0.00073	CcSEcCtD
Regorafenib—Anaemia—Epirubicin—peripheral nervous system neoplasm	7.34e-05	0.000729	CcSEcCtD
Regorafenib—Rash—Etoposide—peripheral nervous system neoplasm	7.29e-05	0.000724	CcSEcCtD
Regorafenib—Dermatitis—Etoposide—peripheral nervous system neoplasm	7.28e-05	0.000724	CcSEcCtD
Regorafenib—Headache—Etoposide—peripheral nervous system neoplasm	7.24e-05	0.00072	CcSEcCtD
Regorafenib—Leukopenia—Epirubicin—peripheral nervous system neoplasm	7.11e-05	0.000706	CcSEcCtD
Regorafenib—Nausea—Etoposide—peripheral nervous system neoplasm	6.87e-05	0.000682	CcSEcCtD
Regorafenib—Hypertension—Epirubicin—peripheral nervous system neoplasm	6.86e-05	0.000681	CcSEcCtD
Regorafenib—Anaemia—Doxorubicin—peripheral nervous system neoplasm	6.79e-05	0.000675	CcSEcCtD
Regorafenib—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—peripheral nervous system neoplasm	6.72e-05	0.000667	CcSEcCtD
Regorafenib—Dry mouth—Epirubicin—peripheral nervous system neoplasm	6.61e-05	0.000657	CcSEcCtD
Regorafenib—Leukopenia—Doxorubicin—peripheral nervous system neoplasm	6.58e-05	0.000654	CcSEcCtD
Regorafenib—Infection—Epirubicin—peripheral nervous system neoplasm	6.44e-05	0.00064	CcSEcCtD
Regorafenib—Nervous system disorder—Epirubicin—peripheral nervous system neoplasm	6.36e-05	0.000632	CcSEcCtD
Regorafenib—Thrombocytopenia—Epirubicin—peripheral nervous system neoplasm	6.35e-05	0.000631	CcSEcCtD
Regorafenib—Hypertension—Doxorubicin—peripheral nervous system neoplasm	6.35e-05	0.00063	CcSEcCtD
Regorafenib—Skin disorder—Epirubicin—peripheral nervous system neoplasm	6.3e-05	0.000626	CcSEcCtD
Regorafenib—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—peripheral nervous system neoplasm	6.21e-05	0.000617	CcSEcCtD
Regorafenib—Dry mouth—Doxorubicin—peripheral nervous system neoplasm	6.12e-05	0.000608	CcSEcCtD
Regorafenib—Infection—Doxorubicin—peripheral nervous system neoplasm	5.96e-05	0.000592	CcSEcCtD
Regorafenib—Nervous system disorder—Doxorubicin—peripheral nervous system neoplasm	5.88e-05	0.000584	CcSEcCtD
Regorafenib—Thrombocytopenia—Doxorubicin—peripheral nervous system neoplasm	5.87e-05	0.000583	CcSEcCtD
Regorafenib—Skin disorder—Doxorubicin—peripheral nervous system neoplasm	5.83e-05	0.000579	CcSEcCtD
Regorafenib—Decreased appetite—Epirubicin—peripheral nervous system neoplasm	5.64e-05	0.00056	CcSEcCtD
Regorafenib—Gastrointestinal disorder—Epirubicin—peripheral nervous system neoplasm	5.6e-05	0.000556	CcSEcCtD
Regorafenib—Fatigue—Epirubicin—peripheral nervous system neoplasm	5.59e-05	0.000555	CcSEcCtD
Regorafenib—Pain—Epirubicin—peripheral nervous system neoplasm	5.54e-05	0.000551	CcSEcCtD
Regorafenib—Gastrointestinal pain—Epirubicin—peripheral nervous system neoplasm	5.3e-05	0.000527	CcSEcCtD
Regorafenib—Decreased appetite—Doxorubicin—peripheral nervous system neoplasm	5.21e-05	0.000518	CcSEcCtD
Regorafenib—Gastrointestinal disorder—Doxorubicin—peripheral nervous system neoplasm	5.18e-05	0.000514	CcSEcCtD
Regorafenib—Fatigue—Doxorubicin—peripheral nervous system neoplasm	5.17e-05	0.000514	CcSEcCtD
Regorafenib—Pain—Doxorubicin—peripheral nervous system neoplasm	5.13e-05	0.00051	CcSEcCtD
Regorafenib—Abdominal pain—Epirubicin—peripheral nervous system neoplasm	5.12e-05	0.000509	CcSEcCtD
Regorafenib—Body temperature increased—Epirubicin—peripheral nervous system neoplasm	5.12e-05	0.000509	CcSEcCtD
Regorafenib—Gastrointestinal pain—Doxorubicin—peripheral nervous system neoplasm	4.9e-05	0.000487	CcSEcCtD
Regorafenib—Abdominal pain—Doxorubicin—peripheral nervous system neoplasm	4.74e-05	0.000471	CcSEcCtD
Regorafenib—Body temperature increased—Doxorubicin—peripheral nervous system neoplasm	4.74e-05	0.000471	CcSEcCtD
Regorafenib—Asthenia—Epirubicin—peripheral nervous system neoplasm	4.65e-05	0.000462	CcSEcCtD
Regorafenib—ABCB1—cerebellum—peripheral nervous system neoplasm	4.65e-05	0.00249	CbGeAlD
Regorafenib—Diarrhoea—Epirubicin—peripheral nervous system neoplasm	4.44e-05	0.000441	CcSEcCtD
Regorafenib—Asthenia—Doxorubicin—peripheral nervous system neoplasm	4.3e-05	0.000428	CcSEcCtD
Regorafenib—Vomiting—Epirubicin—peripheral nervous system neoplasm	4.12e-05	0.000409	CcSEcCtD
Regorafenib—Diarrhoea—Doxorubicin—peripheral nervous system neoplasm	4.1e-05	0.000408	CcSEcCtD
Regorafenib—Rash—Epirubicin—peripheral nervous system neoplasm	4.09e-05	0.000406	CcSEcCtD
Regorafenib—Dermatitis—Epirubicin—peripheral nervous system neoplasm	4.08e-05	0.000406	CcSEcCtD
Regorafenib—Headache—Epirubicin—peripheral nervous system neoplasm	4.06e-05	0.000403	CcSEcCtD
Regorafenib—Nausea—Epirubicin—peripheral nervous system neoplasm	3.85e-05	0.000383	CcSEcCtD
Regorafenib—Vomiting—Doxorubicin—peripheral nervous system neoplasm	3.81e-05	0.000379	CcSEcCtD
Regorafenib—Rash—Doxorubicin—peripheral nervous system neoplasm	3.78e-05	0.000376	CcSEcCtD
Regorafenib—Dermatitis—Doxorubicin—peripheral nervous system neoplasm	3.78e-05	0.000375	CcSEcCtD
Regorafenib—Headache—Doxorubicin—peripheral nervous system neoplasm	3.76e-05	0.000373	CcSEcCtD
Regorafenib—Nausea—Doxorubicin—peripheral nervous system neoplasm	3.56e-05	0.000354	CcSEcCtD
Regorafenib—KIT—Immune System—ERBB2—peripheral nervous system neoplasm	6.07e-06	5.17e-05	CbGpPWpGaD
Regorafenib—PDGFRB—Disease—PTPN11—peripheral nervous system neoplasm	6.05e-06	5.15e-05	CbGpPWpGaD
Regorafenib—RAF1—Innate Immune System—NRAS—peripheral nervous system neoplasm	6.03e-06	5.14e-05	CbGpPWpGaD
Regorafenib—FLT4—Signaling Pathways—TP53—peripheral nervous system neoplasm	5.93e-06	5.06e-05	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—NTRK1—peripheral nervous system neoplasm	5.92e-06	5.04e-05	CbGpPWpGaD
Regorafenib—FGFR2—Innate Immune System—HRAS—peripheral nervous system neoplasm	5.91e-06	5.03e-05	CbGpPWpGaD
Regorafenib—RAF1—Immune System—PTPN11—peripheral nervous system neoplasm	5.84e-06	4.97e-05	CbGpPWpGaD
Regorafenib—KIT—Innate Immune System—HRAS—peripheral nervous system neoplasm	5.8e-06	4.94e-05	CbGpPWpGaD
Regorafenib—FLT1—Signaling Pathways—NRAS—peripheral nervous system neoplasm	5.79e-06	4.93e-05	CbGpPWpGaD
Regorafenib—RAF1—Adaptive Immune System—NRAS—peripheral nervous system neoplasm	5.79e-06	4.93e-05	CbGpPWpGaD
Regorafenib—FGFR1—Immune System—ERBB2—peripheral nervous system neoplasm	5.76e-06	4.91e-05	CbGpPWpGaD
Regorafenib—PDGFRA—Immune System—ERBB2—peripheral nervous system neoplasm	5.75e-06	4.9e-05	CbGpPWpGaD
Regorafenib—FGFR2—Disease—ERBB2—peripheral nervous system neoplasm	5.71e-06	4.86e-05	CbGpPWpGaD
Regorafenib—MAPK11—Innate Immune System—AKT1—peripheral nervous system neoplasm	5.68e-06	4.84e-05	CbGpPWpGaD
Regorafenib—FLT4—Signaling Pathways—HRAS—peripheral nervous system neoplasm	5.67e-06	4.84e-05	CbGpPWpGaD
Regorafenib—FGFR2—Adaptive Immune System—HRAS—peripheral nervous system neoplasm	5.67e-06	4.83e-05	CbGpPWpGaD
Regorafenib—ABCG2—Metabolism—GNAS—peripheral nervous system neoplasm	5.67e-06	4.83e-05	CbGpPWpGaD
Regorafenib—KIT—Disease—ERBB2—peripheral nervous system neoplasm	5.6e-06	4.78e-05	CbGpPWpGaD
Regorafenib—ABL1—Hemostasis—TP53—peripheral nervous system neoplasm	5.6e-06	4.77e-05	CbGpPWpGaD
Regorafenib—KIT—Adaptive Immune System—HRAS—peripheral nervous system neoplasm	5.57e-06	4.75e-05	CbGpPWpGaD
Regorafenib—ABCG2—Metabolism—ABCB1—peripheral nervous system neoplasm	5.56e-06	4.74e-05	CbGpPWpGaD
Regorafenib—MAPK11—Signaling Pathways—PTPN11—peripheral nervous system neoplasm	5.51e-06	4.69e-05	CbGpPWpGaD
Regorafenib—FGFR1—Innate Immune System—HRAS—peripheral nervous system neoplasm	5.5e-06	4.69e-05	CbGpPWpGaD
Regorafenib—FGFR1—Developmental Biology—AKT1—peripheral nervous system neoplasm	5.5e-06	4.69e-05	CbGpPWpGaD
Regorafenib—PDGFRA—Innate Immune System—HRAS—peripheral nervous system neoplasm	5.49e-06	4.68e-05	CbGpPWpGaD
Regorafenib—ABL1—Developmental Biology—HRAS—peripheral nervous system neoplasm	5.46e-06	4.65e-05	CbGpPWpGaD
Regorafenib—BRAF—Signaling Pathways—PTPN11—peripheral nervous system neoplasm	5.45e-06	4.65e-05	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—GNAS—peripheral nervous system neoplasm	5.43e-06	4.63e-05	CbGpPWpGaD
Regorafenib—CYP2C8—Metabolism—ENO2—peripheral nervous system neoplasm	5.42e-06	4.62e-05	CbGpPWpGaD
Regorafenib—CYP2B6—Metabolism—BCHE—peripheral nervous system neoplasm	5.41e-06	4.61e-05	CbGpPWpGaD
Regorafenib—FLT1—Signaling Pathways—MYC—peripheral nervous system neoplasm	5.39e-06	4.59e-05	CbGpPWpGaD
Regorafenib—RAF1—Disease—PTPN11—peripheral nervous system neoplasm	5.39e-06	4.59e-05	CbGpPWpGaD
Regorafenib—NTRK1—Signaling Pathways—ERBB2—peripheral nervous system neoplasm	5.36e-06	4.56e-05	CbGpPWpGaD
Regorafenib—ABL1—Hemostasis—HRAS—peripheral nervous system neoplasm	5.35e-06	4.56e-05	CbGpPWpGaD
Regorafenib—FGFR1—Disease—ERBB2—peripheral nervous system neoplasm	5.32e-06	4.53e-05	CbGpPWpGaD
Regorafenib—PDGFRA—Disease—ERBB2—peripheral nervous system neoplasm	5.3e-06	4.52e-05	CbGpPWpGaD
Regorafenib—FGFR1—Adaptive Immune System—HRAS—peripheral nervous system neoplasm	5.29e-06	4.5e-05	CbGpPWpGaD
Regorafenib—PDGFRA—Adaptive Immune System—HRAS—peripheral nervous system neoplasm	5.27e-06	4.49e-05	CbGpPWpGaD
Regorafenib—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—peripheral nervous system neoplasm	5.26e-06	4.49e-05	CbGpPWpGaD
Regorafenib—FGFR2—Innate Immune System—AKT1—peripheral nervous system neoplasm	5.21e-06	4.44e-05	CbGpPWpGaD
Regorafenib—PDGFRB—Immune System—ERBB2—peripheral nervous system neoplasm	5.18e-06	4.41e-05	CbGpPWpGaD
Regorafenib—CYP2B6—Metabolism—SLC2A1—peripheral nervous system neoplasm	5.16e-06	4.4e-05	CbGpPWpGaD
Regorafenib—KIT—Innate Immune System—AKT1—peripheral nervous system neoplasm	5.12e-06	4.36e-05	CbGpPWpGaD
Regorafenib—MAPK11—Immune System—NRAS—peripheral nervous system neoplasm	5.12e-06	4.36e-05	CbGpPWpGaD
Regorafenib—RAF1—Hemostasis—TP53—peripheral nervous system neoplasm	5.12e-06	4.36e-05	CbGpPWpGaD
Regorafenib—CYP2B6—Metabolism—TH—peripheral nervous system neoplasm	5.09e-06	4.34e-05	CbGpPWpGaD
Regorafenib—KDR—Signaling Pathways—ERBB2—peripheral nervous system neoplasm	5.06e-06	4.31e-05	CbGpPWpGaD
Regorafenib—FGFR2—Signaling Pathways—PTPN11—peripheral nervous system neoplasm	5.06e-06	4.31e-05	CbGpPWpGaD
Regorafenib—ABL1—Immune System—ERBB2—peripheral nervous system neoplasm	5.04e-06	4.3e-05	CbGpPWpGaD
Regorafenib—FLT4—Signaling Pathways—AKT1—peripheral nervous system neoplasm	5.01e-06	4.27e-05	CbGpPWpGaD
Regorafenib—FGFR2—Adaptive Immune System—AKT1—peripheral nervous system neoplasm	5.01e-06	4.27e-05	CbGpPWpGaD
Regorafenib—RAF1—Developmental Biology—HRAS—peripheral nervous system neoplasm	4.99e-06	4.25e-05	CbGpPWpGaD
Regorafenib—KIT—Signaling Pathways—PTPN11—peripheral nervous system neoplasm	4.97e-06	4.23e-05	CbGpPWpGaD
Regorafenib—PDGFRB—Innate Immune System—HRAS—peripheral nervous system neoplasm	4.95e-06	4.22e-05	CbGpPWpGaD
Regorafenib—KIT—Adaptive Immune System—AKT1—peripheral nervous system neoplasm	4.92e-06	4.19e-05	CbGpPWpGaD
Regorafenib—RAF1—Hemostasis—HRAS—peripheral nervous system neoplasm	4.9e-06	4.17e-05	CbGpPWpGaD
Regorafenib—NTRK1—Signaling Pathways—CASP3—peripheral nervous system neoplasm	4.86e-06	4.14e-05	CbGpPWpGaD
Regorafenib—FGFR1—Innate Immune System—AKT1—peripheral nervous system neoplasm	4.86e-06	4.14e-05	CbGpPWpGaD
Regorafenib—PDGFRA—Innate Immune System—AKT1—peripheral nervous system neoplasm	4.85e-06	4.13e-05	CbGpPWpGaD
Regorafenib—CYP2C19—Metabolism—ENO2—peripheral nervous system neoplasm	4.84e-06	4.12e-05	CbGpPWpGaD
Regorafenib—ABL1—Innate Immune System—HRAS—peripheral nervous system neoplasm	4.82e-06	4.11e-05	CbGpPWpGaD
Regorafenib—ABL1—Developmental Biology—AKT1—peripheral nervous system neoplasm	4.82e-06	4.11e-05	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—GNS—peripheral nervous system neoplasm	4.8e-06	4.09e-05	CbGpPWpGaD
Regorafenib—PDGFRB—Disease—ERBB2—peripheral nervous system neoplasm	4.78e-06	4.07e-05	CbGpPWpGaD
Regorafenib—PDGFRB—Adaptive Immune System—HRAS—peripheral nervous system neoplasm	4.75e-06	4.05e-05	CbGpPWpGaD
Regorafenib—MAPK11—Gene Expression—MYC—peripheral nervous system neoplasm	4.74e-06	4.04e-05	CbGpPWpGaD
Regorafenib—ABL1—Hemostasis—AKT1—peripheral nervous system neoplasm	4.73e-06	4.03e-05	CbGpPWpGaD
Regorafenib—ABCB1—Metabolism—ENO2—peripheral nervous system neoplasm	4.72e-06	4.02e-05	CbGpPWpGaD
Regorafenib—FGFR1—Signaling Pathways—PTPN11—peripheral nervous system neoplasm	4.71e-06	4.02e-05	CbGpPWpGaD
Regorafenib—FGFR2—Immune System—NRAS—peripheral nervous system neoplasm	4.7e-06	4.01e-05	CbGpPWpGaD
Regorafenib—PDGFRA—Signaling Pathways—PTPN11—peripheral nervous system neoplasm	4.7e-06	4.01e-05	CbGpPWpGaD
Regorafenib—BRAF—Disease—NRAS—peripheral nervous system neoplasm	4.68e-06	3.99e-05	CbGpPWpGaD
Regorafenib—FGFR1—Adaptive Immune System—AKT1—peripheral nervous system neoplasm	4.67e-06	3.98e-05	CbGpPWpGaD
Regorafenib—PDGFRA—Adaptive Immune System—AKT1—peripheral nervous system neoplasm	4.66e-06	3.97e-05	CbGpPWpGaD
Regorafenib—KIT—Immune System—NRAS—peripheral nervous system neoplasm	4.62e-06	3.94e-05	CbGpPWpGaD
Regorafenib—RAF1—Immune System—ERBB2—peripheral nervous system neoplasm	4.61e-06	3.93e-05	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—NME1—peripheral nervous system neoplasm	4.6e-06	3.92e-05	CbGpPWpGaD
Regorafenib—KDR—Signaling Pathways—CASP3—peripheral nervous system neoplasm	4.59e-06	3.91e-05	CbGpPWpGaD
Regorafenib—CYP2C8—Metabolism—BCHE—peripheral nervous system neoplasm	4.58e-06	3.9e-05	CbGpPWpGaD
Regorafenib—ABCB1—Integrated Pancreatic Cancer Pathway—AKT1—peripheral nervous system neoplasm	4.45e-06	3.79e-05	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—COX2—peripheral nervous system neoplasm	4.43e-06	3.78e-05	CbGpPWpGaD
Regorafenib—FLT1—Signaling Pathways—TP53—peripheral nervous system neoplasm	4.43e-06	3.77e-05	CbGpPWpGaD
Regorafenib—CYP2C9—Metabolism—ENO2—peripheral nervous system neoplasm	4.41e-06	3.76e-05	CbGpPWpGaD
Regorafenib—RAF1—Innate Immune System—HRAS—peripheral nervous system neoplasm	4.41e-06	3.76e-05	CbGpPWpGaD
Regorafenib—RAF1—Developmental Biology—AKT1—peripheral nervous system neoplasm	4.41e-06	3.76e-05	CbGpPWpGaD
Regorafenib—FGFR1—Immune System—NRAS—peripheral nervous system neoplasm	4.38e-06	3.73e-05	CbGpPWpGaD
Regorafenib—PDGFRA—Immune System—NRAS—peripheral nervous system neoplasm	4.37e-06	3.73e-05	CbGpPWpGaD
Regorafenib—CYP2C8—Metabolism—SLC2A1—peripheral nervous system neoplasm	4.37e-06	3.72e-05	CbGpPWpGaD
Regorafenib—PDGFRB—Innate Immune System—AKT1—peripheral nervous system neoplasm	4.37e-06	3.72e-05	CbGpPWpGaD
Regorafenib—BRAF—Disease—MYC—peripheral nervous system neoplasm	4.36e-06	3.72e-05	CbGpPWpGaD
Regorafenib—MAPK11—Signaling Pathways—ERBB2—peripheral nervous system neoplasm	4.35e-06	3.71e-05	CbGpPWpGaD
Regorafenib—FGFR2—Disease—NRAS—peripheral nervous system neoplasm	4.34e-06	3.7e-05	CbGpPWpGaD
Regorafenib—RAF1—Hemostasis—AKT1—peripheral nervous system neoplasm	4.32e-06	3.68e-05	CbGpPWpGaD
Regorafenib—BRAF—Signaling Pathways—ERBB2—peripheral nervous system neoplasm	4.31e-06	3.67e-05	CbGpPWpGaD
Regorafenib—CYP2C8—Metabolism—TH—peripheral nervous system neoplasm	4.31e-06	3.67e-05	CbGpPWpGaD
Regorafenib—KIT—Disease—NRAS—peripheral nervous system neoplasm	4.26e-06	3.63e-05	CbGpPWpGaD
Regorafenib—RAF1—Disease—ERBB2—peripheral nervous system neoplasm	4.26e-06	3.63e-05	CbGpPWpGaD
Regorafenib—ABL1—Innate Immune System—AKT1—peripheral nervous system neoplasm	4.26e-06	3.63e-05	CbGpPWpGaD
Regorafenib—PDGFRB—Signaling Pathways—PTPN11—peripheral nervous system neoplasm	4.23e-06	3.61e-05	CbGpPWpGaD
Regorafenib—FLT1—Signaling Pathways—HRAS—peripheral nervous system neoplasm	4.23e-06	3.61e-05	CbGpPWpGaD
Regorafenib—RAF1—Adaptive Immune System—HRAS—peripheral nervous system neoplasm	4.23e-06	3.61e-05	CbGpPWpGaD
Regorafenib—PDGFRB—Adaptive Immune System—AKT1—peripheral nervous system neoplasm	4.19e-06	3.57e-05	CbGpPWpGaD
Regorafenib—CYP2B6—Metabolism—GNAS—peripheral nervous system neoplasm	4.15e-06	3.54e-05	CbGpPWpGaD
Regorafenib—CYP2C19—Metabolism—BCHE—peripheral nervous system neoplasm	4.09e-06	3.48e-05	CbGpPWpGaD
Regorafenib—CYP2B6—Metabolism—ABCB1—peripheral nervous system neoplasm	4.07e-06	3.47e-05	CbGpPWpGaD
Regorafenib—NTRK1—Signaling Pathways—NRAS—peripheral nervous system neoplasm	4.07e-06	3.47e-05	CbGpPWpGaD
Regorafenib—FGFR1—Disease—NRAS—peripheral nervous system neoplasm	4.05e-06	3.45e-05	CbGpPWpGaD
Regorafenib—FGFR2—Disease—MYC—peripheral nervous system neoplasm	4.04e-06	3.45e-05	CbGpPWpGaD
Regorafenib—PDGFRA—Disease—NRAS—peripheral nervous system neoplasm	4.04e-06	3.44e-05	CbGpPWpGaD
Regorafenib—FGFR2—Signaling Pathways—ERBB2—peripheral nervous system neoplasm	4e-06	3.41e-05	CbGpPWpGaD
Regorafenib—ABCB1—Metabolism—BCHE—peripheral nervous system neoplasm	3.99e-06	3.4e-05	CbGpPWpGaD
Regorafenib—KIT—Disease—MYC—peripheral nervous system neoplasm	3.97e-06	3.38e-05	CbGpPWpGaD
Regorafenib—MAPK11—Signaling Pathways—CASP3—peripheral nervous system neoplasm	3.95e-06	3.37e-05	CbGpPWpGaD
Regorafenib—PDGFRB—Immune System—NRAS—peripheral nervous system neoplasm	3.94e-06	3.36e-05	CbGpPWpGaD
Regorafenib—KIT—Signaling Pathways—ERBB2—peripheral nervous system neoplasm	3.92e-06	3.34e-05	CbGpPWpGaD
Regorafenib—BRAF—Signaling Pathways—CASP3—peripheral nervous system neoplasm	3.91e-06	3.33e-05	CbGpPWpGaD
Regorafenib—CYP2C19—Metabolism—SLC2A1—peripheral nervous system neoplasm	3.9e-06	3.32e-05	CbGpPWpGaD
Regorafenib—RAF1—Innate Immune System—AKT1—peripheral nervous system neoplasm	3.89e-06	3.32e-05	CbGpPWpGaD
Regorafenib—KDR—Signaling Pathways—NRAS—peripheral nervous system neoplasm	3.85e-06	3.28e-05	CbGpPWpGaD
Regorafenib—CYP2C19—Metabolism—TH—peripheral nervous system neoplasm	3.84e-06	3.28e-05	CbGpPWpGaD
Regorafenib—RAF1—Signaling by GPCR—NRAS—peripheral nervous system neoplasm	3.84e-06	3.27e-05	CbGpPWpGaD
Regorafenib—ABL1—Immune System—NRAS—peripheral nervous system neoplasm	3.84e-06	3.27e-05	CbGpPWpGaD
Regorafenib—ABCB1—Metabolism—SLC2A1—peripheral nervous system neoplasm	3.81e-06	3.24e-05	CbGpPWpGaD
Regorafenib—NTRK1—Signaling Pathways—MYC—peripheral nervous system neoplasm	3.8e-06	3.23e-05	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—PTPN11—peripheral nervous system neoplasm	3.77e-06	3.22e-05	CbGpPWpGaD
Regorafenib—FGFR1—Disease—MYC—peripheral nervous system neoplasm	3.77e-06	3.21e-05	CbGpPWpGaD
Regorafenib—PDGFRA—Disease—MYC—peripheral nervous system neoplasm	3.76e-06	3.2e-05	CbGpPWpGaD
Regorafenib—ABCB1—Metabolism—TH—peripheral nervous system neoplasm	3.75e-06	3.2e-05	CbGpPWpGaD
Regorafenib—MAPK11—Immune System—HRAS—peripheral nervous system neoplasm	3.75e-06	3.19e-05	CbGpPWpGaD
Regorafenib—FLT1—Signaling Pathways—AKT1—peripheral nervous system neoplasm	3.74e-06	3.19e-05	CbGpPWpGaD
Regorafenib—RAF1—Adaptive Immune System—AKT1—peripheral nervous system neoplasm	3.74e-06	3.19e-05	CbGpPWpGaD
Regorafenib—CYP2C9—Metabolism—BCHE—peripheral nervous system neoplasm	3.73e-06	3.18e-05	CbGpPWpGaD
Regorafenib—FGFR1—Signaling Pathways—ERBB2—peripheral nervous system neoplasm	3.72e-06	3.17e-05	CbGpPWpGaD
Regorafenib—PDGFRA—Signaling Pathways—ERBB2—peripheral nervous system neoplasm	3.71e-06	3.17e-05	CbGpPWpGaD
Regorafenib—PDGFRB—Disease—NRAS—peripheral nervous system neoplasm	3.64e-06	3.1e-05	CbGpPWpGaD
Regorafenib—FGFR2—Signaling Pathways—CASP3—peripheral nervous system neoplasm	3.63e-06	3.09e-05	CbGpPWpGaD
Regorafenib—KDR—Signaling Pathways—MYC—peripheral nervous system neoplasm	3.59e-06	3.06e-05	CbGpPWpGaD
Regorafenib—KIT—Signaling Pathways—CASP3—peripheral nervous system neoplasm	3.56e-06	3.04e-05	CbGpPWpGaD
Regorafenib—CYP2C9—Metabolism—SLC2A1—peripheral nervous system neoplasm	3.56e-06	3.03e-05	CbGpPWpGaD
Regorafenib—CYP2C8—Metabolism—GNAS—peripheral nervous system neoplasm	3.52e-06	3e-05	CbGpPWpGaD
Regorafenib—RAF1—Immune System—NRAS—peripheral nervous system neoplasm	3.51e-06	2.99e-05	CbGpPWpGaD
Regorafenib—CYP2C9—Metabolism—TH—peripheral nervous system neoplasm	3.5e-06	2.99e-05	CbGpPWpGaD
Regorafenib—CYP2C8—Metabolism—ABCB1—peripheral nervous system neoplasm	3.45e-06	2.94e-05	CbGpPWpGaD
Regorafenib—FGFR2—Immune System—HRAS—peripheral nervous system neoplasm	3.44e-06	2.93e-05	CbGpPWpGaD
Regorafenib—BRAF—Disease—HRAS—peripheral nervous system neoplasm	3.43e-06	2.92e-05	CbGpPWpGaD
Regorafenib—PDGFRB—Disease—MYC—peripheral nervous system neoplasm	3.39e-06	2.89e-05	CbGpPWpGaD
Regorafenib—FGFR1—Signaling Pathways—CASP3—peripheral nervous system neoplasm	3.38e-06	2.88e-05	CbGpPWpGaD
Regorafenib—KIT—Immune System—HRAS—peripheral nervous system neoplasm	3.38e-06	2.88e-05	CbGpPWpGaD
Regorafenib—PDGFRA—Signaling Pathways—CASP3—peripheral nervous system neoplasm	3.37e-06	2.87e-05	CbGpPWpGaD
Regorafenib—PDGFRB—Signaling Pathways—ERBB2—peripheral nervous system neoplasm	3.35e-06	2.85e-05	CbGpPWpGaD
Regorafenib—MAPK11—Signaling Pathways—NRAS—peripheral nervous system neoplasm	3.31e-06	2.82e-05	CbGpPWpGaD
Regorafenib—MAPK11—Immune System—AKT1—peripheral nervous system neoplasm	3.31e-06	2.82e-05	CbGpPWpGaD
Regorafenib—MAPK11—Gene Expression—AKT1—peripheral nervous system neoplasm	3.29e-06	2.8e-05	CbGpPWpGaD
Regorafenib—BRAF—Signaling Pathways—NRAS—peripheral nervous system neoplasm	3.28e-06	2.8e-05	CbGpPWpGaD
Regorafenib—RAF1—Disease—NRAS—peripheral nervous system neoplasm	3.24e-06	2.76e-05	CbGpPWpGaD
Regorafenib—FGFR1—Immune System—HRAS—peripheral nervous system neoplasm	3.21e-06	2.73e-05	CbGpPWpGaD
Regorafenib—PDGFRA—Immune System—HRAS—peripheral nervous system neoplasm	3.2e-06	2.73e-05	CbGpPWpGaD
Regorafenib—FGFR2—Disease—HRAS—peripheral nervous system neoplasm	3.18e-06	2.71e-05	CbGpPWpGaD
Regorafenib—CYP2C19—Metabolism—GNAS—peripheral nervous system neoplasm	3.14e-06	2.67e-05	CbGpPWpGaD
Regorafenib—KIT—Disease—HRAS—peripheral nervous system neoplasm	3.12e-06	2.66e-05	CbGpPWpGaD
Regorafenib—NTRK1—Signaling Pathways—TP53—peripheral nervous system neoplasm	3.12e-06	2.66e-05	CbGpPWpGaD
Regorafenib—MAPK11—Signaling Pathways—MYC—peripheral nervous system neoplasm	3.08e-06	2.63e-05	CbGpPWpGaD
Regorafenib—CYP2C19—Metabolism—ABCB1—peripheral nervous system neoplasm	3.08e-06	2.62e-05	CbGpPWpGaD
Regorafenib—ABCB1—Metabolism—GNAS—peripheral nervous system neoplasm	3.06e-06	2.61e-05	CbGpPWpGaD
Regorafenib—BRAF—Signaling Pathways—MYC—peripheral nervous system neoplasm	3.06e-06	2.6e-05	CbGpPWpGaD
Regorafenib—FGFR2—Signaling Pathways—NRAS—peripheral nervous system neoplasm	3.04e-06	2.59e-05	CbGpPWpGaD
Regorafenib—PDGFRB—Signaling Pathways—CASP3—peripheral nervous system neoplasm	3.04e-06	2.59e-05	CbGpPWpGaD
Regorafenib—FGFR2—Immune System—AKT1—peripheral nervous system neoplasm	3.04e-06	2.59e-05	CbGpPWpGaD
Regorafenib—BRAF—Disease—AKT1—peripheral nervous system neoplasm	3.03e-06	2.58e-05	CbGpPWpGaD
Regorafenib—RAF1—Disease—MYC—peripheral nervous system neoplasm	3.02e-06	2.57e-05	CbGpPWpGaD
Regorafenib—KIT—Signaling Pathways—NRAS—peripheral nervous system neoplasm	2.99e-06	2.54e-05	CbGpPWpGaD
Regorafenib—KIT—Immune System—AKT1—peripheral nervous system neoplasm	2.98e-06	2.54e-05	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—ERBB2—peripheral nervous system neoplasm	2.98e-06	2.54e-05	CbGpPWpGaD
Regorafenib—NTRK1—Signaling Pathways—HRAS—peripheral nervous system neoplasm	2.98e-06	2.54e-05	CbGpPWpGaD
Regorafenib—FGFR1—Disease—HRAS—peripheral nervous system neoplasm	2.96e-06	2.52e-05	CbGpPWpGaD
Regorafenib—PDGFRA—Disease—HRAS—peripheral nervous system neoplasm	2.95e-06	2.52e-05	CbGpPWpGaD
Regorafenib—KDR—Signaling Pathways—TP53—peripheral nervous system neoplasm	2.95e-06	2.51e-05	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—ENO2—peripheral nervous system neoplasm	2.91e-06	2.48e-05	CbGpPWpGaD
Regorafenib—PDGFRB—Immune System—HRAS—peripheral nervous system neoplasm	2.88e-06	2.46e-05	CbGpPWpGaD
Regorafenib—CYP2C9—Metabolism—GNAS—peripheral nervous system neoplasm	2.86e-06	2.44e-05	CbGpPWpGaD
Regorafenib—FGFR1—Signaling Pathways—NRAS—peripheral nervous system neoplasm	2.83e-06	2.41e-05	CbGpPWpGaD
Regorafenib—FGFR2—Signaling Pathways—MYC—peripheral nervous system neoplasm	2.83e-06	2.41e-05	CbGpPWpGaD
Regorafenib—FGFR1—Immune System—AKT1—peripheral nervous system neoplasm	2.83e-06	2.41e-05	CbGpPWpGaD
Regorafenib—PDGFRA—Signaling Pathways—NRAS—peripheral nervous system neoplasm	2.83e-06	2.41e-05	CbGpPWpGaD
Regorafenib—PDGFRA—Immune System—AKT1—peripheral nervous system neoplasm	2.82e-06	2.41e-05	CbGpPWpGaD
Regorafenib—KDR—Signaling Pathways—HRAS—peripheral nervous system neoplasm	2.82e-06	2.4e-05	CbGpPWpGaD
Regorafenib—RAF1—Signaling by GPCR—HRAS—peripheral nervous system neoplasm	2.81e-06	2.4e-05	CbGpPWpGaD
Regorafenib—CYP2C9—Metabolism—ABCB1—peripheral nervous system neoplasm	2.81e-06	2.39e-05	CbGpPWpGaD
Regorafenib—ABL1—Immune System—HRAS—peripheral nervous system neoplasm	2.81e-06	2.39e-05	CbGpPWpGaD
Regorafenib—FGFR2—Disease—AKT1—peripheral nervous system neoplasm	2.8e-06	2.39e-05	CbGpPWpGaD
Regorafenib—KIT—Signaling Pathways—MYC—peripheral nervous system neoplasm	2.78e-06	2.37e-05	CbGpPWpGaD
Regorafenib—KIT—Disease—AKT1—peripheral nervous system neoplasm	2.75e-06	2.35e-05	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—CASP3—peripheral nervous system neoplasm	2.71e-06	2.31e-05	CbGpPWpGaD
Regorafenib—PDGFRB—Disease—HRAS—peripheral nervous system neoplasm	2.66e-06	2.27e-05	CbGpPWpGaD
Regorafenib—FGFR1—Signaling Pathways—MYC—peripheral nervous system neoplasm	2.64e-06	2.25e-05	CbGpPWpGaD
Regorafenib—PDGFRA—Signaling Pathways—MYC—peripheral nervous system neoplasm	2.63e-06	2.24e-05	CbGpPWpGaD
Regorafenib—NTRK1—Signaling Pathways—AKT1—peripheral nervous system neoplasm	2.63e-06	2.24e-05	CbGpPWpGaD
Regorafenib—FGFR1—Disease—AKT1—peripheral nervous system neoplasm	2.61e-06	2.23e-05	CbGpPWpGaD
Regorafenib—PDGFRA—Disease—AKT1—peripheral nervous system neoplasm	2.61e-06	2.22e-05	CbGpPWpGaD
Regorafenib—RAF1—Immune System—HRAS—peripheral nervous system neoplasm	2.57e-06	2.19e-05	CbGpPWpGaD
Regorafenib—PDGFRB—Signaling Pathways—NRAS—peripheral nervous system neoplasm	2.55e-06	2.17e-05	CbGpPWpGaD
Regorafenib—PDGFRB—Immune System—AKT1—peripheral nervous system neoplasm	2.54e-06	2.17e-05	CbGpPWpGaD
Regorafenib—MAPK11—Signaling Pathways—TP53—peripheral nervous system neoplasm	2.53e-06	2.16e-05	CbGpPWpGaD
Regorafenib—BRAF—Signaling Pathways—TP53—peripheral nervous system neoplasm	2.51e-06	2.14e-05	CbGpPWpGaD
Regorafenib—KDR—Signaling Pathways—AKT1—peripheral nervous system neoplasm	2.49e-06	2.12e-05	CbGpPWpGaD
Regorafenib—RAF1—Signaling by GPCR—AKT1—peripheral nervous system neoplasm	2.48e-06	2.11e-05	CbGpPWpGaD
Regorafenib—ABL1—Immune System—AKT1—peripheral nervous system neoplasm	2.48e-06	2.11e-05	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—BCHE—peripheral nervous system neoplasm	2.46e-06	2.1e-05	CbGpPWpGaD
Regorafenib—MAPK11—Signaling Pathways—HRAS—peripheral nervous system neoplasm	2.42e-06	2.06e-05	CbGpPWpGaD
Regorafenib—BRAF—Signaling Pathways—HRAS—peripheral nervous system neoplasm	2.4e-06	2.04e-05	CbGpPWpGaD
Regorafenib—PDGFRB—Signaling Pathways—MYC—peripheral nervous system neoplasm	2.37e-06	2.02e-05	CbGpPWpGaD
Regorafenib—RAF1—Disease—HRAS—peripheral nervous system neoplasm	2.37e-06	2.02e-05	CbGpPWpGaD
Regorafenib—PDGFRB—Disease—AKT1—peripheral nervous system neoplasm	2.35e-06	2e-05	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—SLC2A1—peripheral nervous system neoplasm	2.35e-06	2e-05	CbGpPWpGaD
Regorafenib—FGFR2—Signaling Pathways—TP53—peripheral nervous system neoplasm	2.33e-06	1.98e-05	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—TH—peripheral nervous system neoplasm	2.31e-06	1.97e-05	CbGpPWpGaD
Regorafenib—KIT—Signaling Pathways—TP53—peripheral nervous system neoplasm	2.28e-06	1.95e-05	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—NRAS—peripheral nervous system neoplasm	2.27e-06	1.93e-05	CbGpPWpGaD
Regorafenib—RAF1—Immune System—AKT1—peripheral nervous system neoplasm	2.27e-06	1.93e-05	CbGpPWpGaD
Regorafenib—FGFR2—Signaling Pathways—HRAS—peripheral nervous system neoplasm	2.22e-06	1.9e-05	CbGpPWpGaD
Regorafenib—KIT—Signaling Pathways—HRAS—peripheral nervous system neoplasm	2.18e-06	1.86e-05	CbGpPWpGaD
Regorafenib—FGFR1—Signaling Pathways—TP53—peripheral nervous system neoplasm	2.17e-06	1.85e-05	CbGpPWpGaD
Regorafenib—PDGFRA—Signaling Pathways—TP53—peripheral nervous system neoplasm	2.16e-06	1.84e-05	CbGpPWpGaD
Regorafenib—MAPK11—Signaling Pathways—AKT1—peripheral nervous system neoplasm	2.14e-06	1.82e-05	CbGpPWpGaD
Regorafenib—BRAF—Signaling Pathways—AKT1—peripheral nervous system neoplasm	2.12e-06	1.81e-05	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—MYC—peripheral nervous system neoplasm	2.11e-06	1.8e-05	CbGpPWpGaD
Regorafenib—RAF1—Disease—AKT1—peripheral nervous system neoplasm	2.09e-06	1.78e-05	CbGpPWpGaD
Regorafenib—FGFR1—Signaling Pathways—HRAS—peripheral nervous system neoplasm	2.07e-06	1.77e-05	CbGpPWpGaD
Regorafenib—PDGFRA—Signaling Pathways—HRAS—peripheral nervous system neoplasm	2.07e-06	1.76e-05	CbGpPWpGaD
Regorafenib—FGFR2—Signaling Pathways—AKT1—peripheral nervous system neoplasm	1.96e-06	1.67e-05	CbGpPWpGaD
Regorafenib—PDGFRB—Signaling Pathways—TP53—peripheral nervous system neoplasm	1.95e-06	1.66e-05	CbGpPWpGaD
Regorafenib—KIT—Signaling Pathways—AKT1—peripheral nervous system neoplasm	1.93e-06	1.64e-05	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—GNAS—peripheral nervous system neoplasm	1.89e-06	1.61e-05	CbGpPWpGaD
Regorafenib—PDGFRB—Signaling Pathways—HRAS—peripheral nervous system neoplasm	1.86e-06	1.59e-05	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—ABCB1—peripheral nervous system neoplasm	1.85e-06	1.58e-05	CbGpPWpGaD
Regorafenib—FGFR1—Signaling Pathways—AKT1—peripheral nervous system neoplasm	1.83e-06	1.56e-05	CbGpPWpGaD
Regorafenib—PDGFRA—Signaling Pathways—AKT1—peripheral nervous system neoplasm	1.83e-06	1.56e-05	CbGpPWpGaD
Regorafenib—UGT1A1—Metabolism—AKT1—peripheral nervous system neoplasm	1.8e-06	1.54e-05	CbGpPWpGaD
Regorafenib—UGT1A9—Metabolism—AKT1—peripheral nervous system neoplasm	1.8e-06	1.54e-05	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—TP53—peripheral nervous system neoplasm	1.74e-06	1.48e-05	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—HRAS—peripheral nervous system neoplasm	1.66e-06	1.41e-05	CbGpPWpGaD
Regorafenib—PDGFRB—Signaling Pathways—AKT1—peripheral nervous system neoplasm	1.64e-06	1.4e-05	CbGpPWpGaD
Regorafenib—ABCG2—Metabolism—AKT1—peripheral nervous system neoplasm	1.53e-06	1.3e-05	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—AKT1—peripheral nervous system neoplasm	1.47e-06	1.25e-05	CbGpPWpGaD
Regorafenib—CYP2B6—Metabolism—AKT1—peripheral nervous system neoplasm	1.12e-06	9.55e-06	CbGpPWpGaD
Regorafenib—CYP2C8—Metabolism—AKT1—peripheral nervous system neoplasm	9.49e-07	8.09e-06	CbGpPWpGaD
Regorafenib—CYP2C19—Metabolism—AKT1—peripheral nervous system neoplasm	8.47e-07	7.22e-06	CbGpPWpGaD
Regorafenib—ABCB1—Metabolism—AKT1—peripheral nervous system neoplasm	8.27e-07	7.05e-06	CbGpPWpGaD
Regorafenib—CYP2C9—Metabolism—AKT1—peripheral nervous system neoplasm	7.72e-07	6.58e-06	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—AKT1—peripheral nervous system neoplasm	5.09e-07	4.34e-06	CbGpPWpGaD
